Kodiak bags a $34M B round for retinal R&D

Kodiak CEO Victor Perlroth

Ophthalmology biotech Kodiak Sciences raised $34 million in Series B financing to speed up its pipeline of ocular therapies.

The company, founded in 2009, recruited an undisclosed U.S.-based investor to lead the round, earmarking funds for its work on an unnamed disease of the eye. With the fundraise, Kodiak has pulled in more than $60 million for its work, the company said.

Kodiak is keeping its targets under wraps as it works through preclinical studies, putting its new funds toward early-stage research as it develops new therapies for retinal disease.

"This financing is further recognition of the potential of our pipeline and platform in retina," CEO Victor Perlroth said in a statement. "We now move another step closer to our goal of building a long-term and independent retina franchise company for the benefit of patients."

- read the statement

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.